T2I–Associated Conditions

Several medical conditions are commonly associated with type 2 inflammation (T2I). They typically affect the respiratory system, skin, and digestive tract, including:

Respiratory Conditions

Asthma. T2I affects up to 51% of people with uncontrolled asthma and 55% to 70% of people with severe asthma. In asthma, T2I causes airway swelling and tightening, making breathing difficult and leading to coughing, wheezing, and chest tightness.1,2

Chronic obstructive pulmonary disorder (COPD). About 40% of people with this lung disease show evidence of type 2 inflammation. This subtype of COPD typically leads to a greater number of flares, or exacerbations.5,6

Chronic rhinosinusitis with nasal polyps (CRSwNP). This is a chronic inflammatory disease marked by grape-like projections of polyps within the nasal cavity. This leads to congestion, post-nasal drip, facial pressure or pain, runny nose, and loss of smell. About 80% of CRwNP cases have underlying type 2 inflammation. People with CRwNP are also more likely to have asthma.7-9

Skin Conditions

Atopic dermatitis (AD). Also known as eczema, AD is a chronic skin condition marked by dry, itchy, scaly, inflamed patches of skin. With eczema, T2I affects your skin by weakening the skin barrier and causing intense itching and red, scaly patches.1,2

Bullous pemphigoid (BP). An autoimmune blistering disease that mainly occurs in the elderly. T2I plays a central role in BP, with IgE antibodies found in 70% – 85% of patients.11

Chronic spontaneous urticaria (CSU).Also known as chronic hives, is an autoimmune condition marked by recurrent hives, swelling, and itching that may last for months or even years. Increased levels of type 2 inflammatory markers are found in the skin of patients with chronic spontaneous urticaria.12

Prurigo nodularis (PN). This is another chronic skin condition marked by itchy nodules on the legs, arms, and body. While the exact cause of PN isn’t clear, there is clear evidence that T2I plays a role.15

Digestive Conditions

Eosinophilic esophagitis (EoE). This is a chronic condition of the esophagus, the tube that delivers food from the mouth to the stomach. Proteins in food trigger the T2I response, leading to inflammation, trouble swallowing, food getting stuck, and chronic heartburn.2

Food allergies. T2I can cause food allergies by creating specific IgE antibodies to foods causing hives, swelling, and in severe cases, anaphylaxis, a severe, life-threatening allergic reaction.2

How can T2I be diagnosed?

Your healthcare providers can diagnose T2I with skin, blood, and breathing tests, including:

  • Skin prick test. This is the most common way to check for allergies. A doctor places a tiny amount of different allergens on your skin and makes small scratches. If your skin gets red and puffy in any spots, it means you’re allergic to those things. It’s quick, easy, and inexpensive.16
  • IgE test. This blood test measures antibodies called IgE that your body makes when fighting specific allergens. This shows what you’re allergic to.16
  • Blood eosinophil count. Eosinophils are white blood cells that increase during allergic reactions. If you have 150 or more of these cells per microliter of blood, it usually means you have type 2 inflammation. For some lung diseases like COPD, doctors look for levels of 300 or higher to predict who might have worse symptoms.17
  • Exhaled nitric oxide test (FeNO). This simple breathing test measures a gas in your breath called nitric oxide. Higher levels mean you have inflammation in your airways. The results help doctors choose the right medicine for you. Different medications work better depending on your FeNO levels.18
  • Total IgE test. This blood test measures all your allergy antibodies. High levels might mean you have allergies but normal levels don’t rule out inflammation. It’s less precise than other tests but can still be helpful.16

If you have one T2I disease, you’re far more likely to have another. This is called a “comorbid” condition. In fact, nearly six out of 10 people with one T2I condition have at least one other. The good news is that one treatment may help with these other coexisting conditions also affected by T2I.19

References

  1. Allergy and Asthma Network. What is Type 2 Inflammation? https://allergyasthmanetwork.org/health-a-z/type-2-inflammation-resources/
  2. American College of Allergy A, & Immunology. Type 2 Inflammatory Disease. https://acaai.org/type-2-inflammatory-disease/
  3. Lynn SJ, Kushto-Reese K. Understanding asthma pathophysiology, diagnosis and management. American Nurse. July 7, 2015. https://www.myamericannurse.com/understanding-asthma-pathophysiology/
  4. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2025 report. 2025. https://goldcopd.org/2025-gold-report/
  5. Polverino F, Sin DD. Type 2 airway inflammation in COPD. Eur Respir J. 2024;63:2400150
  6. Varricchi G, Poto R. Towards precision medicine in COPD: Targeting type 2 cytokines and alarmins. Eur J Intern Med. 2024;125:28-31.
  7. Chen S, Zhou A, Emmanuel B, Thomas K, Guiang H. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020;36:1897-1911.
  8. Morse JC, Miller C, Senior B. Management of chronic rhinosinusitis with nasal polyposis in the era of biologics. J Asthma Allergy. 2021;14:873-882.
  9. Langdon C, Mullol J. Nasal polyps in patients with asthma: Prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45-53.
  10. Shutterstock. Atopic Dermatitis. https://www.shutterstock.com/image-photo/pattern-atopic-eczema-fungal-diseases-on-2180479667
  11. Zhang L, Chen Z, Wang L, Luo X. Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy. Front Immunol. 2023;14:1115083.
  12. Kolkhir P, Muñoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;149:1819-1831.
  13. Bullous Pemphigoid. https://www.englishdermatology.com/services/bullous-pemphigoid/
  14. Mathur N. New study classifies CSU skin eruptions into five categories using mathematical modeling. News Medical Life Sciences. December 6, 2024. https://www.news-medical.net/news/20231206/New-study-classifies-CSU-skin-eruptions-into-five-categories-using-mathematical-modeling.aspx
  15. DermNet. Nodular prurigo. https://dermnetnz.org/topics/nodular-prurigo
  16. Ansotegui IJ, Melioli G, Canonica GW, et al. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organ J. 2020;13:100080.
  17. Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology. 2020;158:1776-1786.
  18. Maniscalco M, Fuschillo S, Mormile I, et al. Exhaled nitric oxide as biomarker of type 2 diseases. Cells. 2023;12:2518.
  19. Gómez de la Fuente E, Alobid I, Ojanguren I, et al. Addressing the unmet needs in patients with type 2 inflammatory diseases: when quality of life can make a difference. Front Allergy. 2023;4:1296894.

All URLs Accessed February 5, 2025

Pin It on Pinterest

Directory
Scroll to Top

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers